公开(公告)号：US12226484B2

公开(公告)日：2025-02-18

申请号：US18487486

申请日：2023-10-16

Applicant: TRx Biosciences Limited

Inventor： John Brew ,  Daniel Gooding ,  Robin M. Bannister

IPC: A61K47/14 ,  A61K31/05 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/58 ,  A61K31/7135 ,  A61K38/12 ,  A61K47/28

Abstract: The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.

公开(公告)号：US20240075147A1

公开(公告)日：2024-03-07

申请号：US18487486

申请日：2023-10-16

Applicant: TRx Biosciences Limited

Inventor： John Brew ,  Daniel Gooding ,  Robin M. Bannister

IPC: A61K47/14 ,  A61K31/05 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/58 ,  A61K31/7135 ,  A61K38/12 ,  A61K47/28

CPC classification number: A61K47/14 ,  A61K31/05 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4453 ,  A61K31/496 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/58 ,  A61K31/7135 ,  A61K38/12 ,  A61K47/28

Abstract: The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.

公开(公告)号：US20220305125A1

公开(公告)日：2022-09-29

申请号：US17656702

申请日：2022-03-28

Applicant: TRx Biosciences Limited

Inventor： John Brew ,  Daniel Gooding ,  Robin M. Bannister

IPC: A61K47/14 ,  A61K47/28 ,  A61K31/12 ,  A61K31/216 ,  A61K31/05 ,  A61K31/58 ,  A61K31/7135 ,  A61K31/192 ,  A61K31/553 ,  A61K31/4418 ,  A61K31/4453 ,  A61K31/196 ,  A61K31/44 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/502 ,  A61K31/496 ,  A61K31/4025 ,  A61K38/12

Abstract: The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.